Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Method for preventing human glands from radiation injury

A technology for radiation damage and glands, applied in the field of radiation oncology to prevent side effects

Pending Publication Date: 2022-07-12
MERZ THERAPEUTICS GMBH
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is also a taboo here

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for preventing human glands from radiation injury
  • Method for preventing human glands from radiation injury
  • Method for preventing human glands from radiation injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0072] The methods of the present invention are suitable for a variety of applications. It is not only suitable for diagnosing diseases, for which radionuclides or radioligands are used; but also for the treatment of diseases, for which radionuclides or radioligands are used. Exemplary radionuclides include 32 P. 60 Co. 90 Sr, 90 Y. 103 Pd, 125 I. 131 I. 137 Cs, 188 Re, 192 Ir, 198 Au, 226 Ra. Diseases include neoplastic diseases such as bronchial cancer (eg small cell or large cell bronchial carcinoma), colon cancer, breast cancer, prostate cancer, liver cancer, pancreatic cancer, bladder cancer, skin cancer, ovarian cancer, genitourinary tract cancer, adrenal cortex cancer (pheochromocytoma), brain cancer, stomach cancer, kidney cancer, uterine cancer, bone cancer, esophagus cancer, oropharyngeal cancer, testicular cancer, thyroid cancer, adrenocortical cancer, gallbladder cancer, small bowel cancer, anal cancer, pancreatic cancer, Cholangiocarcinoma, cervical c...

Embodiment 1

[0101] Example 1: Use 68 Example of Ga-PSMA, by use of botulinum toxin type A in the diagnostic use of radioligands Bacteriotoxin and anticholinergic drugs to prevent radiation injury

[0102] in an imaging procedure 68 Two weeks prior to diagnostic use of Ga-PSMA, depending on the specific botulinum toxin type A preparation, a total of between 20 and 900 units of botulinum toxin type A, when used or For example 150 units are applied to the relevant glands, such as one or both mandibular glands and / or one or both parotid glands. In use 68 Three days prior to the imaging procedure for Ga-PSMA, additional administration of anticholinergic drugs was initiated. The anticholinergic drug (scopolamine in this case) is administered in the form of one to two transdermal patches every three days. In this case, about 1 mg of scopolamine is released into the systemic circulation at an almost constant rate over 72 hours. Alternatively, the anticholinergic drug is administered o...

Embodiment 2

[0103] Example 2: Use 68 Example of Ga-PSMA, by use of botulinum toxin type B in the diagnostic use of radioligands Bacteriotoxin and anticholinergic drugs to prevent radiation injury

[0104] in an imaging procedure 68 Two weeks prior to diagnostic use of Ga-PSMA, a total of 3,000 units of botulinum toxin type B (eg ) to the desired glands, such as the submandibular glands on one or both sides, and / or in the parotid glands on one or both sides. In use 68 Three days prior to the imaging procedure for Ga-PSMA, additional administration of anticholinergic drugs was initiated. The anticholinergic drug, here scopolamine, is applied in the form of one to two transdermal patches every three days. In this case, about 1 mg of scopolamine is released into the systemic circulation at an almost constant rate over 72 hours. Alternatively, the anticholinergic drug is administered orally daily (two days before the diagnostic procedure, one day before the diagnostic procedure, on t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of radiooncology. The methods according to the invention comprise the use of botulinum toxins and anticholinergic agents to prevent glands from radiation damage and side effects due to radioactive ligands. The method according to the invention further comprises the use of botulinum toxins to prevent the glands from radiation damage, wherein the radiation damage is caused by radioactive ligands. By using the method according to the invention, the invention can provide effective protection of the glands to avoid radiation damage.

Description

technical field [0001] The present invention relates to the field of radiation oncology. Radiation damage to human glands by radioligands can be avoided with the use of botulinum toxin and anticholinergics. An optimized treatment regimen can confer further advantageous properties to the method. This includes diagnostic imaging procedures and treatment procedures. [0002] Background of the Invention [0003] A radioligand is a substance labeled with a radionuclide that binds as a ligand to a target protein, such as a receptor. For example, such radioligands are used in the diagnosis and treatment of neoplastic diseases. A prominent example is the PSMA radionuclide in the diagnosis and treatment of prostate cancer. [0004] PSMA (Prostate Specific Membrane Protein) is a transmembrane protein expressed by prostate cancer cells at up to 1,000 times the level expressed by normal prostate cells. Therefore, PSMA is an ideal target protein for the diagnosis of prostate cancer a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/48A61K51/00A61P5/00A61P35/00C07K14/33A61K31/00
CPCA61K38/4893A61P5/00A61P35/00A61K31/46A61P39/00A61K51/0402Y02A50/30A61K2300/00A61K45/06
Inventor J·米勒R·鲍姆
Owner MERZ THERAPEUTICS GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com